15880-03-2

Usage

Uses

Used in Pharmaceutical Industry:
3-(2,4-DIMETHYLBENZOYL)PROPIONIC ACID is utilized as an active pharmaceutical ingredient for the development of medications aimed at reducing pain and inflammation. Its application is primarily due to its ability to inhibit prostaglandin production, thereby alleviating symptoms associated with various inflammatory conditions.
Used in Treatment of Arthritis:
In the context of arthritis treatment, 3-(2,4-DIMETHYLBENZOYL)PROPIONIC ACID is used as an analgesic and anti-inflammatory agent to manage the pain and swelling associated with the condition. Its effectiveness in this regard stems from its capacity to curb the production of prostaglandins, which are integral to the inflammatory process in arthritis.
Used in Alleviation of Menstrual Cramps:
3-(2,4-DIMETHYLBENZOYL)PROPIONIC ACID is employed as a therapeutic agent for the relief of menstrual cramps. Its use is justified by its analgesic and anti-inflammatory properties, which help to mitigate the discomfort and pain experienced during menstruation.
Used for Mild to Moderate Pain Management:
This chemical compound is also used as an analgesic for the management of mild to moderate pain. Its application in this context is due to its ability to reduce the sensation of pain by inhibiting the prostaglandins that are responsible for pain transmission.
It is crucial to administer 3-(2,4-DIMETHYLBENZOYL)PROPIONIC ACID under the guidance of a healthcare professional to ensure safe usage and to monitor for potential side effects or interactions with other medications.

InChI:InChI=1/C12H14O3/c1-8-3-4-10(9(2)7-8)11(13)5-6-12(14)15/h3-4,7H,5-6H2,1-2H3,(H,14,15)

Upstream product

• 108-30-5 succinic acid anhydride 
• 108-38-3 m-xylene 
• 543-20-4 succinoyl dichloride 

Downstream Products

• 89724-87-8 5-(2,4-Dimethyl-phenyl)-3H-furan-2-one 
• 13621-26-6 4-(2,4-dimethyl-phenyl)-butyric acid 
• 511311-02-7 5-(2,4-Dimethyl-phenyl)-3-[1-(3-nitro-phenyl)-meth-(E)-ylidene]-3H-furan-2-one 
• 511311-00-5 5-(2,4-Dimethyl-phenyl)-3-[1-(3,4,5-trimethoxy-phenyl)-meth-(E)-ylidene]-3H-furan-2-one 
• 150074-87-6 1-(2,4-dimethylphenyl)-1,4-butanediol 
• 1160652-11-8 2-[3-(2,4-dimethylphenyl)-propan-3-on-1-yl]-5-(3,4-dimethoxyphenyl)-1,3,4-oxadiazole 
• 1160652-10-7 2-[3-(2,4-dimethylphenyl)-propan-3-on-1-yl]-5-(4-methoxyphenyl)-1,3,4-oxadiazole 
• 1160652-05-0 2-[3-(2,4-dimethylphenyl)-propan-3-on-1-yl]-5-phenyl-1,3,4-oxadiazole 
• 1160652-07-2 2-[3-(2,4-dimethylphenyl)-propan-3-on-1-yl]-5-(4-chlorophenyl)-1,3,4-oxadiazole 
• 1160652-09-4 2-[3-(2,4-dimethylphenyl)-propan-3-on-1-yl]-5-(4-nitrophenyl)-1,3,4-oxadiazole 
• 1160652-14-1 2-[3-(2,4-dimethylphenyl)-propan-3-on-1-yl]-5-benzyl-1,3,4-oxadiazole 
• 1160652-06-1 2-[3-(2,4-dimethylphenyl)-propan-3-on-1-yl]-5-(2-chlorophenyl)-1,3,4-oxadiazole 
• 1160652-15-2 2-[3-(2,4-dimethylphenyl)-propan-3-on-1-yl]-5-phenoxymethyl-1,3,4-oxadiazole 
• 1259222-98-4 C₁₈H₁₉N₃O₃ 

Relevant academic research and scientific papers

An efficient one-pot synthesis of pyridazinones and phthalazinones using HY-zeolite

Figure represented. The first one-pot synthesis of pyridazinones and phthalazinones from arenes, cyclic anhydrides, and ArNHNH2 in the presence of efficient recyclable heterogeneous catalyst, HY-zeolite, in high yield and short reaction time is reported.

Extracting agent and preparation method thereof, and method for separating rare earth elements including yttrium and lanthanides

The invention belongs to the field of rare earth resource recovery, and provides an extracting agent. The extracting agent comprises alkyl phenyl oxobutyric acid. The alkyl phenyl oxobutyric acid comprises one or more compounds with structures as shown in

Synthesis, anti-convulsant activity and molecular docking study of novel thiazole pyridazinone hybrid analogues

Pyridazinone analogues have been known to be potential candidates for anticonvulsant agents. We have identified several pyridazinone-based anticonvulsant agents. As a continuation to our previous research, a series of hybrid pyridazinone-thiazole connected through amide linkage were designed and synthesized. Among these, compound SP-5F demonstrated significant anticonvulsant activity with median effective dose of 24.38 mg/kg (MES) and 88.23 mg/kg (scPTz). Results of GABA estimation showed a marked increase in the GABA level when compared with control. Molecular docking studies at the active site of GABA receptor, further confirmed the GABA modulatory effects of SP-5F.

An Electrophilic Trifluoromethylthiolation of Silylenol Ethers and β-Naphthols with Diethylaminosulfur Trifluoride and (Trifluoromethyl)trimethylsilane

An efficient and general trifluoromethylthiolation of silylenol ethers and β-naphthols have been accomplished employing the combination of diethylaminosulfur trifluoride (DAST) and (trifluoromethyl)trimethylsilane (CF3TMS) as source of electrophilic trifluoromethylthio moiety for the synthesis of α-trifluoromethylthiolated carbonyl compounds and β-naphthols in good yields. Important features of this method include wide functional group tolerance and use of readily available DAST/CF3TMS. Potential of the methodology was demonstrated via the synthesis of α-trifluoromethylthiolated (+)-4-cholesten-3-one and naphthoquinone. (Figure presented.).

Design, Synthesis, and Pharmacological Screening of Pyridazinone Hybrids as Anticonvulsant Agents

A series of new hybrid benzimidazole containing pyridazinones derivatives were designed and synthesized in accordance with the pharmacophoric requirements essential for the anticonvulsant activity. The synthesized compounds were evaluated for anticonvulsant activity on mice by the gold standard maximal electroshock (MES) and subcutaneous pentylenetetrazole (scPTZ)-induced seizure models. Among the compounds tested, SS-4F showed significant anticonvulsant activity in both the screens with ED50 values of 25.10 and 85.33 mg/kg in the MES and scPTZ screens, respectively. Compound SS-4F emerged as safer and effective anticonvulsant due to its several-fold higher protective indices. Further, the gamma-aminobutyric acid (GABA) estimation result showed a marked increase in the GABA level (1.7-fold) as compared to the control, which was further confirmed by good binding properties with the GABAA receptor.

Ultrasound-promoted Friedel-Crafts acylation of arenes and cyclic anhydrides catalyzed by ionic liquid of [bmim]Br/AlCl3

A simple and efficient method of Friedel-Crafts acylation of arenes with succinic anhydride, phthalic anhydride and glutaric anhydride under the action of 1-butyl-3-ethylimidazolium ([bmim]Br/AlCl3 ([bmim]+) cation (ionic liquid) and ultrasound irradiation is presented. Thy purity of products was tested by GC-MS and their structures evaluated by IR and 1H NMR spectroscopy.

Enzymatic synthesis of chiral γ-amino acids using ω-transaminase

In this study, we successfully synthesized enantiomerically pure (R)- and (S)-γ-amino acids (>99% ee) using ω-transaminase (ω-TA) through kinetic resolution and asymmetric synthesis respectively. The present study demonstrates the high potentiality of ω-TA reaction for the production of chiral γ-amino acids.

Synthesis and biological evaluation of some novel sulfamoylphenyl- pyridazinone as anti-inflammatory agents (Part-II)

Seven novel 6-aryl-2-(p-sulfamoylphenyl)-4,5-dihydropyridazin-3(2H)-ones (2a-g) were synthesized by the condensation of appropriate aroylpropionic acid and 4-hydrazinobenzenesulfonamide hydrochloride in ethanol. Structure of all compounds have been elucidated by elemental analysis, IR, 1H NMR, 13C NMR, DEPT and MS spectrscopy. These compounds were tested for their anti-inflammatory activity in carrageenan-induced rat paw edema model. Compound 2b exhibited anti-inflammatory activity comparable to that of celecoxib (at 5h). Two other compounds 2d and 2g showed promising anti-inflammatory activity (edema reduction more than 80% at 5h). These compounds (2b, 2d and 2g) did not produce any ulceration in gastric region.

Search for new pharmacophore as antimalarial agent: Synthesis and antimalarial activity of some 2(3H)-furanones bearing quinoline moiety

A series of substituted 3-[(substituted-2-chloroquinolin-3-yl)methylene]-5- (substituted-phenyl)-furan-2(3H)-ones (4a-p) have been synthesized and evaluated for their in vitro antimalarial activity against P. falciparum. The title compounds were synthesized by condensing 3-(substituted-benzoyl)propionic acids (3a-d) with substituted 2-chloroquinoline-3-carbaldehydes (2a-d) following modified Perkin's reaction. Compounds 3-[2-chloro-6-methylquinolin-3-yl) methylene]-5-(2,4-dimethyl-phenyl)-furan-2(3H)-one (4n) and 3-[2-chloro-6- methoxyquinolin-3-yl)methylene]-5-(2,4-dimethyl-phenyl)-furan-2(3H)-one (4p) showed promising antimalarial activity with MIC of 10 μg/mL.

Synthesis of quinoline-attached furan-2(3H)-ones having anti-inflammatory and antibacterial properties with reduced gastro-intestinal toxicity and lipid peroxidation

A series of 5-aryl-3-[(2-chloroquinolin-3-yl)methylene] furan-2(3H)- ones (3a-p) were synthesized. The required 3-(substituted benzoyl)propionic acids 2a-d were prepared under Fried?l-Crafts acylation reaction conditions. The substituted 2-chloroquinoline-3-carboxaldehydes 1a-d were synthesized by reaction of substituted phenylethanone oxime with phosphorus oxychloride in presence of dimethylformamide using the Vilsmeier-Haack reaction method. These compounds were screened for their anti-inflammatory and antibacterial activities along with their ulcerogenic and lipid peroxidation potentials. The compounds that showed significant anti-inflammatory activity were further screened for their analgesic activity. The compounds were less toxic in terms of ulcerogenicity as compared to a standard, which was also supported by lipid peroxidation studies. The antibacterial activities were performed against Staphylococcus aureus and Escherichia coli. Compounds 3f, 3n and 3o showed significant activity against both S. aureus and E. coli having an minimum inhibitory concentration (MIC) value of 6.25 μg mL-1. Copyright 2011 (CC) SCS.